中国肿瘤临床
中國腫瘤臨床
중국종류림상
CHINESE JOURNAL OF CLINICAL ONCOLOGY
2014年
9期
566-570
,共5页
李菲%李增军%易树华%章艳茹%冯晓燕%邢立杰%齐军元%赵耀中%邱录贵
李菲%李增軍%易樹華%章豔茹%馮曉燕%邢立傑%齊軍元%趙耀中%邱錄貴
리비%리증군%역수화%장염여%풍효연%형립걸%제군원%조요중%구록귀
慢性淋巴细胞白血病%利妥昔单抗%氟达拉滨%环磷酰胺%抗肿瘤联合化疗方案
慢性淋巴細胞白血病%利妥昔單抗%氟達拉濱%環燐酰胺%抗腫瘤聯閤化療方案
만성림파세포백혈병%리타석단항%불체랍빈%배린선알%항종류연합화료방안
B cell chronic lymphocytic leukemia%rituximab%fludarabine%cyclophosphamide%antineoplastic combined chemother-apy protocol
目的：比较FC（氟达拉滨和环磷酰胺）和FCR（氟达拉滨、环磷酰胺和利妥昔单抗）方案治疗慢性淋巴细胞白血病（CLL）的临床疗效和预后影响。方法：回顾性分析本院2002年12月至2012年1月应用FC或FCR方案治疗的58例CLL患者病例资料，比较两种方案的疗效和预后影响。结果：FC组31例，FCR组27例。FCR组完全缓解（CR）率和总反应率（ORR）均高于FC组（44.4%vs.19.4%，P=0.039；81.5%vs.51.6%，P=0.017）。疗程结束后，FCR组患者获得微小残留病（microscopice residual disease， MRD）阴性比例高于FC组（37.0%vs.12.9%，P=0.032）。FCR和FC组患者中高危遗传学亚组患者PFS较非高危遗传学亚组患者短（P值分别为0.011，0.027），OS时间无明显差别。结论：FCR方案是治疗CLL患者的更为有效的方案。
目的：比較FC（氟達拉濱和環燐酰胺）和FCR（氟達拉濱、環燐酰胺和利妥昔單抗）方案治療慢性淋巴細胞白血病（CLL）的臨床療效和預後影響。方法：迴顧性分析本院2002年12月至2012年1月應用FC或FCR方案治療的58例CLL患者病例資料，比較兩種方案的療效和預後影響。結果：FC組31例，FCR組27例。FCR組完全緩解（CR）率和總反應率（ORR）均高于FC組（44.4%vs.19.4%，P=0.039；81.5%vs.51.6%，P=0.017）。療程結束後，FCR組患者穫得微小殘留病（microscopice residual disease， MRD）陰性比例高于FC組（37.0%vs.12.9%，P=0.032）。FCR和FC組患者中高危遺傳學亞組患者PFS較非高危遺傳學亞組患者短（P值分彆為0.011，0.027），OS時間無明顯差彆。結論：FCR方案是治療CLL患者的更為有效的方案。
목적：비교FC（불체랍빈화배린선알）화FCR（불체랍빈、배린선알화리타석단항）방안치료만성림파세포백혈병（CLL）적림상료효화예후영향。방법：회고성분석본원2002년12월지2012년1월응용FC혹FCR방안치료적58례CLL환자병례자료，비교량충방안적료효화예후영향。결과：FC조31례，FCR조27례。FCR조완전완해（CR）솔화총반응솔（ORR）균고우FC조（44.4%vs.19.4%，P=0.039；81.5%vs.51.6%，P=0.017）。료정결속후，FCR조환자획득미소잔류병（microscopice residual disease， MRD）음성비례고우FC조（37.0%vs.12.9%，P=0.032）。FCR화FC조환자중고위유전학아조환자PFS교비고위유전학아조환자단（P치분별위0.011，0.027），OS시간무명현차별。결론：FCR방안시치료CLL환자적경위유효적방안。
Objective:This study aimed to compare the clinical efficacy and prognosis between rituximab plus fludarabine and cyclophosphamide (FCR) and fludarabine and cyclophosphamide (FC) regimens for patients with chronic lymphocytic leukemia (CLL). Methods:The clinical data of 58 patients with CLL treated with FCR or FC regimens from December 2002 to January 2012 were analyzed retrospectively. Therapy efficacy and prognosis were compared between the two groups. Results:Among the 58 pa-tients, 27 (44.4%) experienced complete remission (CR) in the FCR group and 31 patients (19.4%) experienced CR in the FC group (P=0.039). The overall response rate (ORR) of the FCR group was higher than that of the FC group (81.5%and 51.6%, respectively, P=0.017). Fourteen patients achieved MRD-negative rating after therapy. PFS and OS in MRD-negative patients were superior compared with the MRD-positive group (P=0.000, 0.003). The proportion of MRD-negative patients in the FCR group was higher than that in the FC group (37.0%and 12.9%, respectively, P=0.032). PFS in high-risk genetic patients was lower than that in low-risk genetic patients (P=0.011, 0.027). The OS time between the two groups did not exhibit any difference. Conclusion:FCR produced a high CR and ORR in patients with CLL. Many patients in the FCR group were responsive to the treatment. Thus, FCR could be a more effective regimen than FC for patients with CLL.
